Google DeepMind CEO Says AI-Designed Drugs Are Entering Clinical Trials
Demis Hassabis announced that pharmaceutical drugs designed by AI at Isomorphic Labs are entering clinical trials, marking a new chapter in AlphaFold's journey from protein structure prediction to active drug design.
Google DeepMind CEO and Nobel laureate Demis Hassabis has announced that AI-designed pharmaceutical drugs developed at Isomorphic Labs — Alphabet's dedicated drug discovery venture — are entering clinical trials. The announcement marks the transition of AlphaFold technology from a research tool for understanding protein structures to an active participant in drug design.
Isomorphic Labs, created by Alphabet in 2021, was tasked with reimagining the entire drug discovery process using AI-first principles. The drugs entering trials were designed using computational approaches that build on AlphaFold's protein structure prediction capabilities to model drug-target interactions and optimize molecular properties.
The timing is significant: AlphaFold is now used by over 3 million researchers across more than 190 countries, tackling problems from antimicrobial resistance to heart disease. AlphaFold 3, which predicts how proteins interact with other molecules throughout cells, has expanded the platform's utility for drug discovery, including creating new antibiotics and personalized cancer treatments.
Hassabis indicated that the next frontier for the technology is understanding how genetic mutations cause changes in protein structure and function, eventually enabling personalized medicine where drugs are optimized for each individual's metabolism. While the clinical trial results remain months away, the entry of AI-designed compounds into human testing represents a concrete milestone for the field.